170568-11-3

Upstream product

• 6850-57-3 2-methoxybenzylamine 
• 5241-64-5 BOC-tryptophane 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 170566-37-7 3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)amino]-2-[N-(2-((4-phenyl)piperazin-1-yl)acetyl)amino]propane 
• 170567-70-1 3-(1H-indolin-3-yl)-1-[N-(2-methoxybenzyl)amino]-2-{N-[2-(4-phenylpiperazin-1-yl)acetyl]amino}propane 
• 170568-12-4 2-amino-3-(1H-indol-3-yl)-N-(2-methoxybenzyl)propanamide 

Relevant academic research and scientific papers

Preparation and condensation reactions of a new light-fluorous Mukaiyama reagent: reliable purification with fluorous solid phase extraction for esters and amides

A modified light-fluorous Mukaiyama reagent bearing a C8F17 tag was prepared and examined in ester and amide forming condensation reactions. Following the reactions, the desired product was effectively separated from the fluorous pyridone by-product using a simple fluorous solid phase extraction.

Method of treating gout with certain indole compounds

This invention relates to a method of treating gout with certain indole compounds and other aromatic compounds.

2-acylaminopropanamides as growth hormone secretagogues

This invention provides a series of novel substituted propanamides which are useful in the a physiological condition which may be modulated by an increase in growth hormone. This invention also provides methods for the treatment of such physiological cond

Bisindoles as tachykinin receptor antagonists

This invention provides a series of substituted bisindole propanamides which are useful as tachykinin receptor antagonists and as serotonin agonists. This invention also provides methods for the treatment of related disorders as well as pharmaceutical for

2-Acylaminopropanamines as growth hormone secretagogues

This invention provides a series of substituted propanamines which are useful in treating a physiological condition which may be modulated by an increase in growth hormone. This invention also provides methods for the treatment of such physiological condi

2-Acylaminopropanamides as growth hormone secretagogues

This invention provides a series of substituted propanamides which are useful in the treatment of a physiological condition which may be modulated by an increase in growth hormone. This invention also provides methods for the treatment of such physiologic

3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists

Early structure-activity studies on racemic tryptophan ester and amide NK- 1 antagonists 5-7 led to the discovery that the potency of the series could be markedly increased by moving the carbonyl function in these molecules to an off-chain position as in the 3-aryl-1,2-diacetamidopropane 9. Further medicinal chemistry incorporating this change resulted in the discovery of a novel series of highly potent aryl amino acid derived NK-1 antagonists of the R stereoisomeric series (IC50's = 100 pM to >5 μM). Compounds in this series were shown to be competitive antagonists using an in vitro NK-1 smooth muscle assay, and this data correlated well with observed human NK-1 binding affinities. Two of these agents, (R)-25 and (R)-32, blocked intrathecal NK-1 agonist-driven [Ac-[Arg6, Sar9, Met(O2)11]-substance P 6-11 (Ac-Sar9)] nociceptive behavior in mice. Both compounds potently blocked the neurogenic dural inflammation following trigeminal ganglion stimulation in the guinea pig after intravenous administration. Further, upon oral administration in this model, (R)-32 was observed to be very potent (ID50 = 91 ng/kg) and have a long duration of action (>8 h at 1 μg/kg). Compound (R)-32, designated LY303870, is currently under clinical development as an NK-1 antagonist with a long duration of action.